ArticleOncotarget2018

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.

Amir Noeparast et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.